|
|
||||||||
The Journal of Neurophysiology Vol. 83 No. 5 May 2000, pp. 2610-2615
Copyright ©2000 by the American Physiological Society
1Department of Pharmacology and 2Department of Physiology, University of Arizona Health Sciences Center, Tucson, AZ 85724
Tang, Qingbo,
Ronald M. Lynch,
Frank Porreca, and
Josephine Lai.
Dynorphin A Elicits an Increase in Intracellular Calcium in
Cultured Neurons Via a Non-Opioid, Non-NMDA Mechanism. J. Neurophysiol. 83: 2610-2615, 2000. The opioid
peptide dynorphin A is known to elicit a number of pathological effects
that may result from neuronal excitotoxicity. An up-regulation of this
peptide has also been causally related to the dysesthesia associated
with inflammation and nerve injury. These effects of dynorphin A are
not mediated through opioid receptor activation but can be effectively
blocked by pretreatment with N-methyl-D-aspartate (NMDA) receptor
antagonists, thus implicating the excitatory amino acid system as a
mediator of the actions of dynorphin A and/or its fragments. A direct
interaction between dynorphin A and the NMDA receptors has been well
established; however the physiological relevance of this interaction
remains equivocal. This study examined whether dynorphin A elicits a
neuronal excitatory effect that may underlie its activation of the NMDA receptors. Calcium imaging of individual cultured cortical neurons showed that the nonopioid peptide dynorphin A(2-17) induced a time- and
dose-dependent increase in intracellular calcium. This excitatory
effect of dynorphin A(2-17) was insensitive to
(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine (MK-801) pretreatment in NMDA-responsive cells. Thus dynorphin A
stimulates neuronal cells via a nonopioid, non-NMDA mechanism. This
excitatory action of dynorphin A could modulate NMDA receptor activity
in vivo by enhancing excitatory neurotransmitter release or by
potentiating NMDA receptor function in a calcium-dependent manner.
Further characterization of this novel site of action of dynorphin A
may provide new insight into the underlying mechanisms of dynorphin
excitotoxicity and its pathological role in neuropathy.
This article has been cited by other articles:
![]() |
M. P. Davis and M. Angst In Reply J. Clin. Oncol., July 10, 2008; 26(20): 3465 - 3465. [Full Text] [PDF] |
||||
![]() |
M. Terashvili, H.-e. Wu, R. J. Leitermann, H.-S. Sun, A. D. Clithero, and L. F. Tseng Differential Mechanisms of Antianalgesia Induced by Endomorphin-1 and Endomorphin-2 in the Ventral Periaqueductal Gray of the Rat J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1257 - 1265. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Koetzner, X.-Y. Hua, J. Lai, F. Porreca, and T. Yaksh Nonopioid Actions of Intrathecal Dynorphin Evoke Spinal Excitatory Amino Acid and Prostaglandin E2 Release Mediated by Cyclooxygenase-1 and -2 J. Neurosci., February 11, 2004; 24(6): 1451 - 1458. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-E. Wu, H.-S. Sun, M. Darpolar, R. J. Leitermann, J. P. Kampine, and L. F. Tseng Dynorphinergic Mechanism Mediating Endomorphin-2-Induced Antianalgesia in the Mouse Spinal Cord J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1135 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Laughlin, A. A. Larson, and G. L. Wilcox Mechanisms of Induction of Persistent Nociception by Dynorphin J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 6 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lai, M. H. Ossipov, T. W. Vanderah, T. P. Malan Jr., and F. Porreca Neuropathic Pain: The Paradox of Dynorphin Mol. Interv., August 1, 2001; 1(3): 160 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Wang, L. R. Gardell, M. H. Ossipov, T. W. Vanderah, M. B. Brennan, U. Hochgeschwender, V. J. Hruby, T. P. Malan Jr, J. Lai, and F. Porreca Pronociceptive Actions of Dynorphin Maintain Chronic Neuropathic Pain J. Neurosci., March 1, 2001; 21(5): 1779 - 1786. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |